益杰立科

Epigenic Therapeutics to present preclinical update of company's epigenome editing technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver.

Epigenic Therapeutics Announced to be listed in “Forbes Asia 100 To Watch 2024” Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”. In the future，our company will continue to deepen research in the life sciences field，consistently strengthen the innovative capabilities and strive to provide safer and more effective treatment options for chronic disease patients. Our goal is to maintain the leading position of the epigenetic therapy, take more treatment options to patients worldwide and promote the widespread application of gene regulation therapies. Read the full list: https://lnkd.in/gW8a8kfU

"No single tool or medication can solve all problems, particularly when it comes to chronic diseases, due to their multi-gene regulated nature," says Baohong Zhang, Co-founder and CEO of Epigenic Therapeutics, in a recent interview with Zhangtongshe. Zhang highlighted the company's strides in R&D and the transformation of scientific research. He emphasized that enterprises need to determine the most appropriate application scenarios for epigenetics based on the state of the disease and develop suitable targets. In August 2023, Qiming co-led Epigenic Therapeutics' Series A financing of $32 million. It is the only company dedicated to the innovative field of epigenetic gene therapy in China. #QMportfolio #QMhealthcare #interview #quotes #Epigenetics #ChronicDisease #GeneTherapy #RnD #QimingVenturePartners